Vertex Pharmaceuticals Incorporated Financial Analysis
Current Price: $428.34 +0.76%
Market Cap: $108.72B
Sector: Healthcare
P/E Ratio: 29.32
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment o
Report Contents
- Income Statement Analysis (5-year history)
- Balance Sheet Overview
- Cash Flow Statement
- Key Financial Ratios
- Valuation Metrics (P/E, EV/EBITDA, P/S)
- Peer Comparison
- Revenue & Earnings Growth Trends
- Margin Analysis
- Analyst Price Targets
- DCF Valuation Model